Association of estrogen receptor α gene PvuII and XbaI polymorphisms with non-small cell lung cancer

  • Authors:
    • Huai-Lu Chang
    • Yu-Jen Cheng
    • Chung-Kuang Su
    • Meng-Chih  Chen
    • Fu-Hsin Chang
    • Fu-Gong Lin
    • Li-Feng Liu
    • Shyng-Shiou   F. Yuan
    • Ming-Chih Chou
    • Chien-Fu Huang
    • Chi-Chiang Yang
  • View Affiliations

  • Published online on: November 15, 2011     https://doi.org/10.3892/ol.2011.482
  • Pages: 462-468
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Single nucleotide polymorphisms (SNPs) of the estrogen receptor (ER)-α have been found to be associated with various diseases at significantly different frequencies. However, whether any relationship exists between ER-α polymorphisms and lung cancer remains to be determined. In this study, 84 non‑smoking, female, non-small cell lung cancer patients with various stages of disease and 234 cancer-free reference controls were enrolled to examine the association of ER-α polymorphisms in lung cancer. Two restriction SNP sites, PvuII and XbaI, in the first intron of the ER-α gene were genotyped by polymerase chain reaction-restriction fragment length polymorphism. The frequencies of the PvuII-XbaI haplotypes and genotypes in a Taiwanese population were revealed for the first time. Although the genotypic frequencies of two polymorphic sites of ER– α were in linkage disequilibrium for the lung cancer group (χ2=50.013, d.f.=4) and reference controls (χ2=60.797, d.f.=4); and 7 and 8 combined genotypes were present, respectively, the distribution and the major genotypes are different in the two groups (p<0.0001). The p-values for PvuII and XbaI genotypes were significantly different between the lung cancer and reference controls. The PP genotype presence was found to be significantly lower in the lung cancer group (P=0.005), whereas presence of the xx genotype was significantly higher (P=0.042). These findings suggested that the PP genotype had a lower risk of lung cancer; whereas the xx genotype had a higher risk. In comparison with other studies conducted in various populations, it is of note that the pX haplotype frequency of this study was higher than that of other studies, whereas the px haplotype was lower. Moreover, the Xx genotypic frequency of XbaI polymorphisms in the ER-α gene of the reference control group was found to be extremely high, whereas the xx genotypic frequency was extremely low. In conclusion, PvuII‑XbaI polymorphisms of the ER-α gene were found to be associated with the risk, but not cancer severity, of non-small cell lung cancer in a Taiwanese population.

Introduction

Estrogens affect the growth, differentiation and function of numerous target tissues, including breast, uterus, vagina, ovary, testis, epididymis and prostate (1,2). The biological effects of estrogens are mediated primarily through high-affinity binding to estrogen receptors (ERs) (3). ERs are nuclear receptor proteins that have an estrogen binding domain and a DNA binding domain (4). There are two types of ERs, ER-α and ER-β. Findings of a previous study indicated that ER-β may not have the same physiological function as ER-α but may instead play a cofunctional role that is dependent upon the presence of ER-α (5). ER and the ER-regulated progesterone receptor are of special interest as their protein levels are always elevated in premalignant and malignant cancer cells (6,7). ERs are overexpressed in human breast cancers and associated with differentiated tumors and with a more favorable prognosis (7). The ER is regarded as one of the significant prognostic factors for breast and lung cancers (810). It has also been suggested that the combined overexpression of epidermal growth factor receptor and ER-α in non-small cell lung cancer patients is predictive of poor outcome and, thus, is a valuable prognostic factor (11). Moreover, ER has been used as a target for lung cancer therapy (12). Therefore, inhibition of the synthesis of ER-α has become one of the major strategies for the prevention and treatment of cancer patients (13,14).

The association between genetic polymorphisms in the ER-α gene and the risk of breast cancer has been a subject that has attracted much interest. Variations in a number of DNA sequences in the ER-α gene have been reported (1517). PvuII and XbaI polymorphisms were mapped onto the ER-α gene intron 1 region, located approximately 50 bp apart. PvuII and XbaI polymorphisms were found to be correlated to breast cancer incidence at a younger age (15,18,19). Recently, the association of ER-α genetic polymorphisms with lung cancer has attracted much attention since ER acts as a hormone-dependent transcriptional regulator, which may play a significant role in the development of lung cancer (12,2023). Moreover, the relationship between the ER gene and the risk of lung cancer has also been reported (23,24). However, in light of its potential biological significance in lung cancer, ER expression in the human lung has been understudied (23). Nevertheless, the association between polymorphisms of XbaI and PvuII in the ER-α gene and lung cancer risk remain to be determined.

Risk of developing lung cancer is known to be affected by the level of consumption and duration of smoking. The percentage of female smokers in Taiwan is very low; however, lung cancer is currently becoming the first cause of death from cancer in females (25). To exclude the risk factors of smoking and gender for lung cancer, 84 non-smoking, female, non-small cell lung cancer patients and 234 cancer-free reference controls were enrolled to investigate the association between ER-α PvuII-XbaI polymorphisms and lung cancer in Taiwan.

Materials and methods

Patients

This study was approved by the Human Ethics Committee of Kaohsiung Armed Forces General Hospital, Kaohsiung, Taiwan. Informed consent to use the tissues for research purposes was obtained from all patients prior to collection. The study participants included 84 non-smoking, female patients, age ranging from 38 to 83 years (median 63.2), who were diagnosed with non-small cell lung cancer in E-Da Hospital, Kaohsiung Armed Forces General Hospital, or Chung Shan Medical University Hospital from January 2006 to July 2009. Of the 84 patients, 27 had clinical stage I, 30 had stage II, 12 had stage III and 15 had stage IV cancer. Another 234 female, non-smoking, cancer-free reference cases, age ranging from 34 to 77 years (median 60.4), were recruited from dental outpatients at Kaohsiung Armed Forces General Hospital or Chung Shan Medical University Hospital. Information regarding gender, age, past histories of smoking and medical illness was obtained from the medical charts or by personal inquiry. Subjects were also excluded if they reported having been smokers.

DNA extraction

The genomic DNA of the lung cancer patients and reference cases were extracted from peripheral blood mononuclear cells using the commercial DNA isolation kit (Qiagen, Valencia, CA, USA), according to the manufacturer’s instructions. Genomic DNA from control cases was extracted from peripheral blood mononuclear cells. In brief, the tissues were ground prior to extraction. Samples were first lysed in the supplied lysis buffer containing proteinase K, incubated for a suitable period and then the lysates were loaded onto the supplied genomic column. DNA was bound to the column while other cell constituents passed through. Following removal of the remaining contaminants by two wash steps, the purified high-molecular-weight DNA was eluted and precipitated with isopropanol and dissolved in 50 μl distilled water. The quality of the isolated DNA was examined in 1% agarose gel stained with ethidium bromide. The DNA concentration was determined by a spectrophotometer, 2–10 ng of genomic DNA was used for each polymerase chain reaction (PCR).

PCR-restriction fragment length polymorphism (PCR-RFLP)

ER-α genotypes were determined using a PCR-RFLP method reported previously (3335), with certain modifications. The primers used for the analysis were: 5′-CTGCCACCCTATCT GTATCTTTTCCTATTCTCC-3′ (forward) and 5′-TCTTTCTC TGCCACCCTGGCGTCGATTATCTGA-3′ (reverse). These primers generated a 1.3-kb fragment. The PCR was performed in a thermal cycler (Perkin-Elmer PCR Thermal Cycler, Perkin-Elmer, Wellesley, MA, USA). Each 50 μl of PCR mixture contained 10 ng of DNA, 1X PCR buffer [50 mM KCl, 10 mM Tris-HCl (pH 9.0)], 2.5 mM MgCl2, 0.16 mM deoxynucleoside triphosphate, 0.5 μM of each primer and 1.5 units of TaqDNA polymerase. The reaction mixture was initially denatured at 94°C for 3 min, followed by 36 cycles of 94°C for 45 sec, 61°C for 45 sec and 72°C for 2 min. The PCR was completed by a final extension cycle at 72°C for 7 min. The product contained a part of intron 1 of the ER-α gene. The PCR products were then digested by the PvuII and XbaI restriction endonucleases, respectively. The DNA fragments were separated using 1.5% agarose gel and detected by ethidium bromide staining. P and X, signified by the absence of restriction sites, yielded a 1.3-kb fragment. p, signified by the presence of PvuII restriction sites on the two alleles, was digested into two fragments (0.85 and 0.45 kb). The x genotype was digested by XbaI into two fragments (0.9 and 0.4 kb). The laboratory staff were blind to the identity of the subjects. Quality control samples were included in genotyping assays.

Statistical analysis

Genotypic distributions were examined for significant departure from the Hardy-Weinburg equilibrium by a goodness-of-fit χ2 test. The χ2 test statistical method was employed to evaluate the lung cancer group and reference group differences in the distribution of genotypes. The χ2 test was also used to test the ER-α PvuII and XbaI polymorphisms and cancer severity. Statistical tests were two-sided. These analyses yielded hazard ratios and 95% confidence intervals. P<0.05 was considered statistically significant.

Results

High-quality DNA was obtained by the Qiagen spin column method from 84 non-small cell lung cancer patients and 234 cancer-free reference cases. Using PCR-RFLP, two restriction SNP sites, PvuII and XbaI, in the first intron of the ER-α gene from the tissue samples of lung cancer patients were genotyped. Fig. 1 shows the DNA fragments indicating different genotypes separated on an agarose gel.

The allele frequencies were in Hardy-Weinberg equilibrium in the groups studied. Table I shows detailed statistical analysis results of ER-α PvuII and XbaI polymorphisms with lung cancer risk. Among the cases with PvuII genotyped in this study, approximately 28.6% (24/84) of the lung cancer group and 43.6% (102/234) in the reference control group were homozygous (PP and pp genotypes), while 71.4% (60/84) of the lung cancer cases and 56.4% (132/234) of the reference controls were heterozygous (Pp genotype). For XbaI, approximately 41.4% (36/84) of the lung cancer group and 29.1% (68/234) in the reference control group were homozygous (XX and xx genotypes), while 57.1% (48/84) of the lung cancer cases and 70.9% (166/234) of the reference controls were heterozygous (Xx genotype). The p-values for PvuII and XbaI genotypes were significantly different between the lung cancer group and reference controls. Although the genotype frequencies of the two polymorphic sites of ER-α were in linkage disequilibrium for the lung cancer group (χ2=50.013, d.f.=4) and reference controls (χ2=60.797, d.f.=4), and 7 and 8 combined genotypes were present, respectively, the distribution and the major genotypes were found to be different in the two groups (p<0.0001). This is the first study to show the haplotypes and allele frequencies of PvuII and XbaI polymorphisms in the ER-α gene of a Taiwanese population. Furthermore, Table II lists the presence of ER-α PvuII-XbaI polymorphisms in samples of various stages of lung cancer. Analysis by the Fisher’s exact test suggests that there was no association between the ER-α PvuII and XbaI polymorphisms and cancer severity.

Table I

The statistical analysis of ER-PvuII and XbaI polymorphisms with lung cancer risk.

Table I

The statistical analysis of ER-PvuII and XbaI polymorphisms with lung cancer risk.

GroupGene genotypes, n (%)P-value
PvuIIPPPppp
 Lung cancer (n=84)3 (3.6)60 (71.4)21 (25.0)0.005
 Reference controls (n=234)40 (17.1)132 (56.4)62 (26.5)
XbaIXXXxxx
 Lung cancer (n=84)9 (10.7)48 (57.1)27 (32.1)0.042
 Reference controls (n=234)23 (9.8)166 (70.9)45 (19.2)
PvuII and XbaIPPXXPPXxPPxxPpXXPpXxPpxxppXXppXxppxx
 Lung cancer (n=84)3 (3.6)003 (3.6)45 (53.6)12 (14.3)3 (3.6)3 (3.6)15 (17.9)<0.0001
 Reference controls (n=234)13 (5.6)21 (9.0)6 (2.6)10 (4.3)110 (47.0)12 (5.1)035 (15.0)27 (11.5)

Table II

Presence of ER-α PvuII and XbaI polymorphisms in samples of different stages of lung cancer.

Table II

Presence of ER-α PvuII and XbaI polymorphisms in samples of different stages of lung cancer.

GenotypeStage IStage IIStage IIIStage IV
PPXX1101
PPXx0000
PPxx0000
PpXX0111
PpXx171846
Ppxx4332
ppXX1101
ppXx0111
ppxx4533

Discussion

The ER-α gene has been associated with elevated lung cancer risk (12,20,21,2628). However, the association between polymorphisms of XbaI and PvuII in the ER-α gene and the risk of developing lung cancer remains unknown. With the exception of lung cancer, a number of other diseases including breast cancer (15,19,29), Alzheimer’s disease (30), obesity (31,32), multiple sclerosis (33), endometriosis (34), uterine leiomyomas (35) and bone mineral density (32,36), have been evaluated for possible linkage with the two PvuII and XbaI polymorphism loci in the ER-α gene. Various ER-α genotypes may determine the differences in ER-α expression rather than impact on the final effects of ER-α (37). In China, breast cancer patients who carried the pp genotype of PvuII in the ER-α gene had an earlier onset of the disease than women carrying the PP or Pp genotype (16). In Norway, no difference was found in the allele frequency ratio of the PvuII polymorphism between 360 breast cancer patients and 672 controls. However, the frequency of allele x of the XbaI polymorphism in breast cancer patients was 1.4 times higher than that in the controls (3840).

The induction of cell proliferation by estrogens has been found in breast adenocarcinomas, and since the presence of ER has been demonstrated in lung tumors, a similar role of estrogens in the development of lung cancer has been proposed. ERs reportedly inhibit proliferation and invasion of breast and lung cancer cells (7,28). Extranuclear forms of ER play a role in promoting downstream signaling for hormone-mediated proliferation and survival of breast as well as lung cancers and offer a new target for anti-tumor therapy (22). Findings of a study in Japan suggested that ER-α expression and the absence of ER-β expression are associated with a poorer prognosis among non-small cell lung cancer patients (23). In the present study, the frequencies of PvuII-XbaI haplotypes and genotypes in a Taiwanese population were revealed for the first time. Consistent with previous studies regarding the ER-α gene as a susceptibility gene for lung cancer (23), an association between the PvuII-XbaI polymorphisms and non-small cell lung cancer was proposed. Previous studies have suggested that PP homozygotes are protective against endometriosis, adenomyosis and leiomyomata (41), whereas XX homozygotes are protective against breast cancer and endometriosis (42,43). Our results demonstrated that presence of the PP genotype is significantly lower in the lung cancer group, whereas prescence of the xx genotype is significantly higher (Table I). These findings suggest that the PP genotype has a lower risk of lung cancer, whereas the xx genotype has a higher risk. Our results also demonstrated that the frequencies of PvuII-XbaI haplotypes are evenly distributed as 20.5, 24.8, 24.8 and 29.9% for PX, Px, pX and px, respectively. In comparison with other studies conducted in different populations, it is of note that the pX haplotype frequency of this study is higher than that of other frequencies, whereas the px haplotype is lower (Table III). Moreover, the Xx genotype frequency of XbaI polymorphisms in the ER-α gene of the reference control group is extremely high, whereas the xx genotype frequency is extremely low (Table IV). The allele frequencies in the reference group of this study were in Hardy-Weinberg equilibrium. It is unclear as to whether the allele frequencies in other studies were in Hardy-Weinberg equilibrium and, thus, this was the cause of discrepancy. Further studies with regard to other ethnic groups are required to confirm whether our findings are applicable to different populations other than Taiwanese populations.

Table III

Comparison of the PvuII-XbaI haplotype frequencies of the human estrogen receptor-α gene in various ethnic groups.

Table III

Comparison of the PvuII-XbaI haplotype frequencies of the human estrogen receptor-α gene in various ethnic groups.

PvuII and XbaI haplotypes (%)Subject no.Country/regionAuthor group (Refs)

PXPxpXpx
20.524.824.829.9234TaiwanThis study
18.726.50.354.5238JapanKobayashi et al (44)
18.322.3059.42226JapanYamada et al (45)
9.520.622.047.973JapanNiino et al (46)
7.935.910.246.0551JapanKazama et al (47)
6.828.412.452.4125ChinaLin et al (48)
18.522.32.357.7598KoreaHan et al (49)
8.630.413.447.6219KoreaKoh et al (50)
6.230.710.652.5268KoreaLee et al (51)
33.713.3053.0454DenmarkBagger et al (52)
36.110.9053.01100NetherlandsVan Meurs et al (53)
50.013.6036.819United States (African)Van Meurs et al (53)
33.59.21.256.1206United KingdomAlbagha et al (54)
40.95.71.352.1610ItalyBecherini et al (55)
35.69.5054.9662CanadaPatel et al (56)
17.324.410.947.464PolandJakimiuk et al (57)

Table IV

Comparison of the PvuII-XbaI allele frequency of the human estrogen receptor-α gene with other studies.

Table IV

Comparison of the PvuII-XbaI allele frequency of the human estrogen receptor-α gene with other studies.

GeneGenotypes, n (%)Subject no.Country/regionAuthor group (Refs)
PvuIIPPPppp
40 (17.1)132 (56.4)62 (26.5)234TaiwanThe present study
43 (24.0)71 (39.7)65 (36.3)179JapanKitawaki et al (41)
371 (16.7)1058 (47.5)797 (35.8)2226JapanYamada et al (45)
6 (8.2)32 (43.8)35 (47.9)73JapanNiino et al (46)
114 (20.7)255 (46.3)182 (33.0)551JapanKazama et al (47)
37 (21.5)88 (51.2)47 (27.3)172JapanWang et al (58)
12 (15.0)36 (45.0)32 (40.0)80JapanKikuchi et al (59)
16 (12.8)56 (44.8)53 (42.4)125ChinaLin et al (48)
36 (16.4)98 (44.7)85 (38.8)219KoreaKoh et al (50)
44 (16.4)110 (41.1)114 (42.5)268KoreaLee et al (51)
33 (21.2)77 (49.4)46 (29.5)156ItalyMassart et al (35)
134 (22.0)299 (49.0)177 (29.0)610ItalyBecherini et al (55)
132 (19.9)333 (50.3)197 (29.8)662CanadaPatel et al (56)
11 (17.2)32 (50.0)21 (32.8)64PolandJakimiuk et al (57)
25 (25.0)48 (48.0)27 (27.0)100GreeceGeorgiou et al (60)
XbaIXXXxxx
23 (9.8)166 (70.9)45 (19.2)234TaiwanThe present study
78 (3.5)642 (28.8)1506 (67.7)2226JapanYamada et al (45)
7 (9.6)32 (43.8)34 (46.6)73JapanNiino et al (46)
20 (3.6)159 (28.9)372 (67.5)551JapanKazama et al (47)
12 (7.0)56 (32.8)103 (60.2)171JapanWang et al (58)
8 (6.4)32 (25.6)85 (68.0)125ChinaLin et al (48)
11 (5.0)75 (34.2)133 (60.7)219KoreaKoh et al (50)
14 (5.2)62 (23.1)192 (71.1)268KoreaLee et al (51)
31 (19.9)70 (44.9)55 (35.2)156ItalyMassart et al (35)
117 (19.2)280 (45.9)213 (34.9)610ItalyBecherini et al (55)
82 (12.4)307 (46.3)273 (41.2)662CanadaPatel et al (56)
4 (6.25)22 (34.4)38 (59.4)64PolandJakimiuk et al (57)

In conclusion, as demonstrated in this study, the PvuII and XbaI polymorphisms of the ER-α gene were associated with the risk, but not cancer severity, of non-small cell lung cancer in a Taiwanese population. However, regarding the association of the ER-α gene polymorphisms with non-small cell lung cancer, our results were based on a relatively modest sample size. The biological pathway for PvuII and XbaI that may affect oncogenesis remains unknown, although it is known that the intronic polymorphism of the ER-α gene may affect its protein synthesis and function as a modulator of the ligand estrogen (7,41). Moreover, with the exception of the ER-α PvuII and XbaI polymorphisms, there may also be numerous confounding factors between the groups, such as smoking and family histories and occupational exposures. Nevertheless, our findings should be applied to other ethnic groups and should be confirmed using larger scale samples as well as other aspects and various factors with non-small cell lung cancer.

Acknowledgements

This study was funded by grants from E-Da Hospital and I-Shou University, Taiwan (EDH95008 and ISU96-04-15) and Chung Shan Medical University (CSMU-LMC-097-001).

References

1 

Nagai MA and Brentani MM: Gene expression profiles in breast cancer to identify estrogen receptor target genes. Mini Rev Med Chem. 8:448–454. 2008. View Article : Google Scholar : PubMed/NCBI

2 

Ko YJ and Balk SP: Targeting steroid hormone receptor pathways in the treatment of hormone dependent cancers. Curr Pharm Biotechnol. 5:459–470. 2004. View Article : Google Scholar : PubMed/NCBI

3 

Zimmermann J and von Angerer E: Estrogenic and antiestrogenic activities of 2,4-diphenylfuran-based ligands of estrogen receptors alpha and beta. J Steroid Biochem Mol Biol. 104:259–268. 2007. View Article : Google Scholar : PubMed/NCBI

4 

Dunn CA, Clark W, Black EJ and Gillespie DA: Estrogen receptor activation function 2 (AF-2) is essential for hormone-dependent transactivation and cell transformation induced by a v-Jun DNA binding domain-estrogen receptor chimera. Biochim Biophys Acta. 1628:147–155. 2003. View Article : Google Scholar

5 

Couse JF, Lindzey J, Grandien K, Gustafsson JA and Korach KS: Tissue distribution and quantitative analysis of estrogen receptor-α (ER-α) and estrogen receptor-α (ER-α) messenger ribonucleic acid in the wild-type and ER-α knockout mouse. Endocrinology. 11:353–365. 1997.

6 

Shen R, Tao L, Xu Y, Chang S, Van Brocklyn J and Gao JX: Reversibility of aberrant global DNA and estrogen receptor-alpha gene methylation distinguishes colorectal precancer from cancer. Int J Clin Exp Pathol. 2:21–33. 2009.PubMed/NCBI

7 

Maynadier M, Nirde P, Ramirez JM, Cathiard AM, Platet N, Chambon M and Garcia M: Role of estrogens and their receptors in adhesion and invasiveness of breast cancer cells. Adv Exp Med Biol. 617:485–491. 2008. View Article : Google Scholar : PubMed/NCBI

8 

Somlo G, Frankel P, Chow W, Leong L, Margolin K, Morgan R Jr, Shibata S, Chu P, Forman S, Lim D, et al: Prognostic indicators and survival in patients with stage IIIB inflammatory breast carcinoma after dose-intense chemotherapy. J Clin Oncol. 22:1839–1848. 2004. View Article : Google Scholar : PubMed/NCBI

9 

Ha SA, Lee YS, Shin SM, et al: Oncoprotein HCCR-1 expression in breast cancer is well correlated with known breast cancer prognostic factors including the HER2 overexpression, p53 mutation, and ER/PR status. BMC Cancer. 9:512009. View Article : Google Scholar : PubMed/NCBI

10 

Bilalović N, Vranić S, Hasanagić S, Basić H, Tatarević A, Beslija S and Selak I: The Bcl-2 protein: a prognostic indicator strongly related to ER and PR in breast cancer. Bosn J Basic Med Sci. 4:5–12. 2004.PubMed/NCBI

11 

Kawai H, Ishii A, Washiya K, Konno T, Kon H, Yamaya C, Ono I and Ogawa J: Combined overexpression of EGFR and estrogen receptor alpha correlates with a poor outcome in lung cancer. Anticancer Res. 25:4693–4698. 2005.PubMed/NCBI

12 

Giovannini M, Belli C, Villa E and Gregorc V: Estrogen receptor (ER) and epidermal growth factor receptor (EGFR) as targets for dual lung cancer therapy: not just a case? J Thorac Oncol. 3:684–685. 2008. View Article : Google Scholar : PubMed/NCBI

13 

Messina M, McCaskill-Stevens W and Lampe JW: Addressing the soy and breast cancer relationship: review, commentary, and workshop proceedings. J Natl Cancer Inst. 98:1275–1284. 2006. View Article : Google Scholar : PubMed/NCBI

14 

Zhou JR, Yu L, Mai Z and Blackburn GL: Combined inhibition of estrogen-dependent human breast carcinoma by soy and tea bioactive components in mice. Int J Cancer. 108:8–14. 2004. View Article : Google Scholar : PubMed/NCBI

15 

Boyapati SM, Shu XO, Ruan ZX, Cai Q, Smith JR, Wen W, Gao YT and Zheng W: Polymorphisms in ER-alpha gene interact with estrogen receptor status in breast cancer survival. Clin Cancer Res. 11:1093–1098. 2005.PubMed/NCBI

16 

Hu Z, Song CG, Lu JS, Luo JM, Shen ZZ, Huang W and Shao ZM: A multigenic study on breast cancer risk associated with genetic polymorphisms of ER alpha, COMT and CYP19 gene in BRCA1/BRCA2 negative Shanghai women with early onset breast cancer or affected relatives. J Cancer Res Clin Oncol. 133:969–978. 2007. View Article : Google Scholar : PubMed/NCBI

17 

Sobczuk A, Pertynski T, Smolarz B and Romanowicz-Makowska H: The analysis of estrogen receptor alpha (ER-alpha) gene Pvull and Xbal polymorphisms in postmenopausal women with breast cancer. Pol Merkur Lekarski. 25:43–45. 2008.PubMed/NCBI

18 

Onland-Moret NC, van Gils CH, Roest M, Grobbee DE and Peeters PH: The estrogen receptor alpha gene and breast cancer risk (The Netherlands). Cancer Causes Control. 16:1195–1202. 2005. View Article : Google Scholar : PubMed/NCBI

19 

Shin A, Kang D, Nishio H, et al: Estrogen receptor alpha gene polymorphisms and breast cancer risk. Breast Cancer Res Treat. 80:127–131. 2003. View Article : Google Scholar : PubMed/NCBI

20 

Marquez-Garban DC, Chen HW, Fishbein MC, Goodglick L and Pietras RJ: Estrogen receptor signaling pathways in human non-small cell lung cancer. Steroids. 72:135–143. 2007. View Article : Google Scholar : PubMed/NCBI

21 

Schwartz AG, Wenzlaff AS, Prysak GM, Murphy V, Cote ML, Brooks SC, Skafar DF and Lonardo F: Reproductive factors, hormone use, estrogen receptor expression and risk of non small-cell lung cancer in women. J Clin Oncol. 25:5785–5792. 2007. View Article : Google Scholar : PubMed/NCBI

22 

Pietras RJ, Marquez DC, Chen HW, Tsai E, Weinberg O and Fishbein M: Estrogen and growth factor receptor interactions in human breast and non-small cell lung cancer cells. Steroids. 70:372–381. 2005. View Article : Google Scholar : PubMed/NCBI

23 

Kawai H, Ishii A, Washiya K, Konno T, Kon H, Yamaya C, Ono I, Minamiya Y and Ogawa J: Estrogen receptor alpha and beta are prognostic factors in non-small cell lung cancer. Clin Cancer Res. 11:5084–5089. 2005. View Article : Google Scholar : PubMed/NCBI

24 

Mollerup S, Jorgensen K, Berge G and Haugen A: Expression of estrogen receptors alpha and beta in human lung tissue and cell lines. Lung Cancer. 37:153–159. 2002. View Article : Google Scholar : PubMed/NCBI

25 

Department of Health (DOH). 2010 statistics of causes of death, DOH, Executive Yuan, R.O.C. (Taiwan). 2011

26 

Stabile LP and Siegfried JM: Estrogen receptor pathways in lung cancer. Curr Oncol Rep. 6:259–267. 2004. View Article : Google Scholar : PubMed/NCBI

27 

Stabile LP, Lyker JS, Gubish CT, Zhang W, Grandis JR and Siegfried JM: Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects. Cancer Res. 65:1459–1470. 2005. View Article : Google Scholar

28 

Hershberger PA, Vasquez AC, Kanterewicz B, Land S, Siegfried JM and Nichols M: Regulation of endogenous gene expression in human non-small cell lung cancer cells by estrogen receptor ligands. Cancer Res. 65:1598–1605. 2005. View Article : Google Scholar : PubMed/NCBI

29 

Cai Q, Shu XO, Jin F, Dai Q, Wen W, Cheng JR, Gao YT and Zheng W: Genetic polymorphisms in the estrogen receptor alpha gene and risk of breast cancer: results from the Shanghai Breast Cancer Study. Cancer Epidemiol Biomarkers Prev. 12:853–859. 2003.PubMed/NCBI

30 

Schupf N, Lee JH, Wei M, Pang D, Chace C, Cheng R, Zigman WB, Tycko B and Silverman W: Estrogen receptor-alpha variants increase risk of Alzheimer’s disease in women with Down syndrome. Dement Geriatr Cogn Disord. 25:476–482. 2008.

31 

Nilsson M, Dahlman I, Ryden M, Nordström EA, Gustafsson JA, Arner P and Dahlman-Wright K: Oestrogen receptor alpha gene expression levels are reduced in obese compared to normal weight females. Int J Obes. 31:900–907. 2007. View Article : Google Scholar : PubMed/NCBI

32 

Jian WX, Yang YJ, Long JR, Li YN, Deng FY, Jiang DK and Deng HW: Estrogen receptor alpha gene relationship with peak bone mass and body mass index in Chinese nuclear families. J Hum Genet. 50:477–482. 2005. View Article : Google Scholar : PubMed/NCBI

33 

Hoshi M, Yasuoka H and Kuwana M: Estrogen receptor gene polymorphisms in Japanese patients with systemic sclerosis. Clin Exp Rheumatol. 26:914–917. 2008.PubMed/NCBI

34 

Kitawaki J, Kado N, Ishihara H, Koshiba H, Kitaoka Y and Honjo H: Endometriosis: the pathophysiology as an estrogen-dependent disease. J Steroid Biochem Mol Biol. 83:149–155. 2002. View Article : Google Scholar : PubMed/NCBI

35 

Massart F, Becherini L, Gennari L, Facchini V, Genazzani AR and Brandi ML: Genotype distribution of estrogen receptor-alpha gene polymorphisms in Italian women with surgical uterine leiomyomas. Fertil Steril. 75:567–570. 2001. View Article : Google Scholar : PubMed/NCBI

36 

Välimäki VV, Piippo K, Välimäki S, Löyttyniemi E, Kontula K and Välimäki MJ: The relation of the XbaI and PvuII polymorphisms of the estrogen receptor gene and the CAG repeat polymorphism of the androgen receptor gene to peak bone mass and bone turnover rate among young healthy men. Osteoporos Int. 16:1633–1640. 2005.

37 

Hill SM, Fuqua SAW, Chamness GC, Greene GL and McGuire WL: Estrogen receptor expression in human breast cancer associated with an estrogen receptor gene restriction fragment length polymorphism. Cancer Res. 49:145–148. 1989.PubMed/NCBI

38 

Kamby C, Rose C, Iversen H, Holm NV, Andersen KW and Thorpe SM: Pattern of metastases in breast cancer and the relation to estrogen receptor status. Ugeskr Laeger. 148:2546–2548. 1986.PubMed/NCBI

39 

Andersen J and Poulsen HS: Relationship between estrogen receptor status in the primary tumor and its regional and distant metastases. An immunohistochemical study in human breast cancer. Acta Oncol. 27:761–765. 1988. View Article : Google Scholar

40 

Talman ML, Rasmussen BB, Andersen J and Christensen IJ: Estrogen receptor analyses in the Danish Breast Cancer Cooperative Group. History, methods, prognosis and clinical implications. Acta Oncol. 47:789–794. 2008. View Article : Google Scholar

41 

Kitawaki J, Obayashi H, Ishihara H, Koshiba H, Kusuki I, Kado N, Tsukamoto K, Hasegawa G, Nakamura N and Honjo H: Oestrogen receptor-alpha gene polymorphism is associated with endometriosis, adenomyosis and leiomyomata. Hum Reprod. 16:51–55. 2001. View Article : Google Scholar : PubMed/NCBI

42 

Andersen TI, Heimdal KR, Skrede M, Tveit K, Berg K and Børresen AL: Oestrogen receptor (ESR) polymorphisms and breast cancer susceptibility. Hum Genet. 94:665–670. 1994.PubMed/NCBI

43 

Weiderpass E, Persson I, Melhus H, Wedrén S, Kindmark A and Baron JA: Estrogen receptor alpha gene polymorphisms and endometrial cancer risk. Carcinogenesis. 21:623–627. 2000. View Article : Google Scholar : PubMed/NCBI

44 

Kobayashi S, Inoue S, Hosoi T, Ouchi Y, Shiraki M and Orimo H: Association of bone mineral density with polymorphism of the estrogen receptor gene. J Bone Miner Res. 11:306–311. 1996. View Article : Google Scholar : PubMed/NCBI

45 

Yamada Y, Ando F, Niino N, Ohta S and Shimokata H: Association of polymorphisms of the estrogen receptor alpha gene with bone mineral density of the femoral neck in elderly Japanese women. J Mol Med. 80:452–460. 2002. View Article : Google Scholar : PubMed/NCBI

46 

Niino M, Kikuchi S, Fukazawa T, Yabe I and Tashiro K: Estrogen receptor gene polymorphism in Japanese patients with multiple sclerosis. J Neurol Sci. 179:70–75. 2000. View Article : Google Scholar : PubMed/NCBI

47 

Kazama H, Ruberu NN, Murayama S, Saito Y, Nakahara K, Kanemaru K, Nagura H, Arai T, Sawabe M, Yamanouchi H, et al: Association of estrogen receptor alpha gene polymorphisms with neurofibrillary tangles. Dement Geriatr Cogn Disord. 18:145–150. 2004. View Article : Google Scholar : PubMed/NCBI

48 

Lin GF, Ma QW, Zhang DS, Zha YL, Lou KJ and Shen JH: Polymorphism of alpha-estrogen receptor and aryl hydrocarbon receptor genes in dementia patients in Shanghai suburb. Acta Pharmacol Sin. 24:651–656. 2003.PubMed/NCBI

49 

Han KO, Moon IG, Kang YS, Chung HY, Min HK and Han IK: Nonassociation of estrogen receptor genotypes with bone mineral density and estrogen responsiveness to hormone replacement therapy in Korean postmenopausal women. J Clin Endocrinol Metab. 82:991–995. 1997. View Article : Google Scholar : PubMed/NCBI

50 

Koh JM, Nam-Goong IS, Hong JS, Kim HK, Kim JS, Kim SY and Kim GS: Oestrogen receptor alpha genotype, and interactions between vitamin D receptor and transforming growth factor-beta1 genotypes are associated with quantitative calcaneal ultrasound in postmenopausal women. Clin Endocrinol. 60:232–240. 2004. View Article : Google Scholar

51 

Lee YJ, Shin KS, Kang SW, Lee CK, Yoo B, Cha HS, Koh EM, Yoon SJ and Lee J: Association of the oestrogen receptor alpha gene polymorphisms with disease onset in systemic lupus erythematosus. Ann Rheum Dis. 63:1244–1249. 2004. View Article : Google Scholar : PubMed/NCBI

52 

Bagger YZ, Jørgensen HL, Heegaard AM, Bayer L, Hansen L and Hassager C: No major effect of estrogen receptor gene polymorphisms on bone mineral density or bone loss in postmenopausal Danish women. Bone. 26:111–116. 2000. View Article : Google Scholar : PubMed/NCBI

53 

Van Meurs JB, Schuit SC, Weel AE, van der Klift M, Bergink AP, Arp PP, Colin EM, Fang Y, Hofman A, van Duijn CM, et al: Association of 5' estrogen receptor alpha gene polymorphisms with bone mineral density, vertebral bone area and fracture risk. Hum Mol Genet. 12:1745–1754. 2003.

54 

Albagha OM, Pettersson U, Stewart A, McGuigan FE, MacDonald HM, Reid DM and Ralston SH: Association of oestrogen receptor alpha gene polymorphisms with postmenopausal bone loss, bone mass, and quantitative ultrasound properties of bone. J Med Genet. 42:240–246. 2005. View Article : Google Scholar : PubMed/NCBI

55 

Becherini L, Gennari L, Masi L, Mansani R, Massart F, Morelli A, Falchetti A, Gonnelli S, Fiorelli G, Tanini A and Brandi ML: Evidence of a linkage disequilibrium between polymorphisms in the human estrogen receptor alpha gene and their relationship to bone mass variation in postmenopausal Italian women. Hum Mol Genet. 9:2043–2050. 2000. View Article : Google Scholar

56 

Patel MS, Cole DE, Smith JD, Hawker GA, Wong B, Trang H, Vieth R, Meltzer P and Rubin LA: Alleles of the estrogen receptor alpha-gene and an estrogen receptor cotranscriptional activator gene, amplified in breast cancer-1 (AIB1), are associated with quantitative calcaneal ultrasound. J Bone Miner Res. 15:2231–2239. 2000. View Article : Google Scholar

57 

Jakimiuk A, Nowicka M, Bogusiewicz M, Adamiak A, Skorupski P, Miotla P, Rechberger T and Haczynski J: Prevalence of estrogen receptor alpha PvuII and XbaI polymorphism in population of Polish postmenopausal women. Folia Histochem Cytobiol. 45:331–338. 2007.PubMed/NCBI

58 

Wang Z, Yoshida S, Negoro K, Kennedy S, Barlow D and Maruo T: Polymorphisms in the estrogen receptor beta gene but not estrogen receptor alpha gene affect the risk of developing endometriosis in a Japanese population. Fertil Steril. 81:1650–1656. 2004. View Article : Google Scholar : PubMed/NCBI

59 

Kikuchi S, Fukazawa T, Niino M, Yabe I, Miyagishi R, Hamada T and Tashiro K: Estrogen receptor gene polymorphism and multiple sclerosis in Japanese patients: interaction with HLA-DRB1*1501 and disease modulation. J Neuroimmunol. 128:77–81. 2002.PubMed/NCBI

60 

Georgiou I, Konstantelli M, Syrrou M, Messinis IE and Lolis DE: Oestrogen receptor gene polymorphisms and ovarian stimulation for in-vitro fertilization. Hum Reprod. 12:1430–1433. 1997. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

February 2012
Volume 3 Issue 2

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Chang H, Cheng Y, Su C, Chen M, Chang F, Lin F, Liu L, Yuan SF, Chou M, Huang C, Huang C, et al: Association of estrogen receptor α gene PvuII and XbaI polymorphisms with non-small cell lung cancer. Oncol Lett 3: 462-468, 2012
APA
Chang, H., Cheng, Y., Su, C., Chen, M., Chang, F., Lin, F. ... Yang, C. (2012). Association of estrogen receptor α gene PvuII and XbaI polymorphisms with non-small cell lung cancer. Oncology Letters, 3, 462-468. https://doi.org/10.3892/ol.2011.482
MLA
Chang, H., Cheng, Y., Su, C., Chen, M., Chang, F., Lin, F., Liu, L., Yuan, S. F., Chou, M., Huang, C., Yang, C."Association of estrogen receptor α gene PvuII and XbaI polymorphisms with non-small cell lung cancer". Oncology Letters 3.2 (2012): 462-468.
Chicago
Chang, H., Cheng, Y., Su, C., Chen, M., Chang, F., Lin, F., Liu, L., Yuan, S. F., Chou, M., Huang, C., Yang, C."Association of estrogen receptor α gene PvuII and XbaI polymorphisms with non-small cell lung cancer". Oncology Letters 3, no. 2 (2012): 462-468. https://doi.org/10.3892/ol.2011.482